Release Summary

Alexion Pharmaceuticals, Inc. announced NICE has recommended Soliris® (eculizumab) be commissioned for all patients in England suffering from atypical hemolytic uremic syndrome (aHUS).

Alexion Pharmaceuticals, Inc.